Best of November: Top 5 Insights In Outsourced Drug Development & Manufacturing

#1 Big Pharma Advises Biotech On Outsourcing

They say biotech taught pharma how to outsource. So what’s someone who has spent 31 years working in Big Pharma know about outsourcing from the vantage point of smaller organizations? A lot, it turns out.

#2 Be An Informed Project Sponsor: Three Trends To Know Before Selecting Your CDMO

Learn more about the desire for deeper collaboration between innovator companies and their CDMO partners, why companies are seeking robust drug development capabilities in-house, and why even global sponsors continue to seek partners based in the U.S.

#3 Here’s Why Outsourcing To CDMOs Doubled In 13 Years

It might surprise no one that BioPlan Associates' 20th annual survey on manufacturing found an increased dependence on contract manufacturing. The sheer rate at which demand has grown, however, is stunning, and the survey found CDMO capacity is only now starting to catch up with supply.

#4 Finding Your Best CDMO Fit For Small Molecule, Sterile Injectable Fill/Finish

"One stop” sterile injectable fill/finish capabilities can accelerate timelines and reduce costs. Explore August Bio’s operational flexibility and available capacity to support small-, mid-size, and large-scale batches.

#5 How To Lose A Batch In 10 Days

This article spotlights the critical missteps that could lead you to lose a batch during the manufacturing process. By identifying these pitfalls, the author guides you toward best practices that will not only save your batches but also improve the quality, efficiency, and reliability of your operations.